A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler® (Symb NIS)
This study has been completed.
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00532922
First received: September 20, 2007
Last updated: June 8, 2009
Last verified: June 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler® |
Resource links provided by NLM:
Further study details as provided by AstraZeneca:
| Enrollment: | 310 |
| Study Start Date: | April 2007 |
| Study Completion Date: | November 2007 |
| Groups/Cohorts |
|---|
|
1
Chinese asthma patient prescribed Symbicort® Turbuhaler®
|
Eligibility| Ages Eligible for Study: | 6 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Natural History, longitudinal, defined population
Criteria
Inclusion Criteria:
- Provision of informed consent
- Asthmatics who has been prescribed Symbicort according to physician's judgement
- Usage of Symbicort should follow local prescribing information
Exclusion Criteria:
- Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
- No previous enrolment in the present study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00532922
Locations
| China, Anhui | |
| Research Site | |
| Hefel, Anhui, China | |
| China, Fujian | |
| Research Site | |
| Fuzhou, Fujian, China | |
| China, Guangdong | |
| Research Site | |
| Guangzhou, Guangdong, China | |
| Research Site | |
| Shenzhen, Guangdong, China | |
| China, Henan | |
| Research Site | |
| Zhengzhou, Henan, China | |
| China, Hubei | |
| Research Site | |
| Wuhan, Hubei, China | |
| China, Hubel | |
| Research Site | |
| Wuhan, Hubel, China | |
| China, Jiangsu | |
| Research Site | |
| Nanjong, Jiangsu, China | |
| Research Site | |
| Suzhou, Jiangsu, China | |
| China, Liaoning | |
| Research Site | |
| Shenyand, Liaoning, China | |
| China, Shandong | |
| Research Site | |
| Qingdao, Shandong, China | |
| China, Shanxi | |
| Research Site | |
| Taiyuan, Shanxi, China | |
| Research Site | |
| Xi'an, Shanxi, China | |
| China, Sichuan | |
| Research Site | |
| Chengdu, Sichuan, China | |
| China, Zhejiang | |
| Research Site | |
| Wenzhou, Zhejiang, China | |
| China | |
| Research Site | |
| Beijing, China | |
| Research Site | |
| Chongqing, China | |
| Research Site | |
| Hangzhou, China | |
| Research Site | |
| Shanghai, China | |
Sponsors and Collaborators
AstraZeneca
Investigators
| Principal Investigator: | Zhou Xin | Shanghai First People's Hospital |
| Principal Investigator: | Hong Jianguo | Shanghai First People's Hospital |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00532922 History of Changes |
| Other Study ID Numbers: | NIS-RCN-SYM-2006/1 |
| Study First Received: | September 20, 2007 |
| Last Updated: | June 8, 2009 |
| Health Authority: | Not required for this study: |
Additional relevant MeSH terms:
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Symbicort Budesonide Anti-Asthmatic Agents |
Respiratory System Agents Therapeutic Uses Pharmacologic Actions Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Inflammatory Agents |
ClinicalTrials.gov processed this record on May 22, 2013